By SPC News Staff
The FDA granted approval to Mylan Pharmaceuticals to manufacture a generic form of cyclosporine ophthalmic emulsion (Restasis, AbbVie), a prescription immunomodulator with anti-inflammatory effects that can help increase tear production in patients who have ocular inflammation associated with keratoconjunctivitis sicca.
The medication, available in 0.05% single-use vials, is the first complex generic approved to alleviate symptoms of keratoconjunctivitis sicca, according to the